Overview
Characterization of patients with steatotic liver disease (SLD)
The German SLD-Registry (Deutsches SLD-Register) a project of the German Liver Foundation (Deutsche Leberstiftung), managed by Leberstiftungs-GmbH Deutschland.
The German NAFLD-Registry is financially supported by: Advanz Pharma Specialty Medicine Deutschland GmbH und Gilead Sciences GmbH (Grant to German Livber Foundation) sowie Novo Nordisk Pharma GmbH (directly via Leberstiftungs-GmbH).
Description
The following data can be documented:
- physical examination and vital parameters (e.g. age, weight)
- comorbidities (e.g. diabetes mellitus, cardiovascular disease)
- comedication (treatment of comorbidities related to SLD)
- laboratory values (e.g. liver function tests, creatinine)
- genetic variants (e.g. PNPLA3)
- liver diagnostics (e.g. histological findings, sonographic findings)
- lifestyle (alcohol consumption, physical activity)
- health related quality of life (SF-36 questionnaire)
Eligibility
Inclusion Criteria:
- diagnosed SLD based on the following criteria:
- typical finding of hepatic steatosis (abdominal ultrasound and/or pathological CAP value (latter is optional)
- Evaluation of SLD degree by NAFLD Fibrosis score and/or FIB-4-Index and/or transient elastography
- Evaluation of metabolic syndrome
- credible assessment of alcohol consumption
- written informed consent
Exclusion Criteria:
- patients with other hepatologic diseases (chronically viral, metabolic, autoimmune origin
- patients receiving hepatotoxic medications over a longer period (e.g. methotrexate, amiodarone, longterm NSAR intake)
- malignant disease with a life expectancy <12 months
- participation in clinical interventional/pivotal studies
- inability to provide written informed consent